

1. Record Nr.	UNINA9910817002103321
Titolo	Clinical applications of mifepristone (RU 486) and other antiprogestins : assessing the science and recommending a research agenda // Committee on Antiprogestins: Assessing the Science, Division of Health Promotion and Disease Prevention, Institute of Medicine ; Molla S. Donaldson ... [et al.], editors
Pubbl/distr/stampa	Washington, D.C., : National Academy Press, 1993
ISBN	1-280-19602-5 9786610196029 0-309-59835-4 0-585-02478-2
Edizione	[1st ed.]
Descrizione fisica	xi, 288 p. : ill
Altri autori (Persone)	BenetLeslie Z DonaldsonMolla S
Disciplina	615/.766
Soggetti	Mifepristone - Research Abortifacients - Research Progesterone - Antagonists - Research
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"Support for this project was provided by a grant from the Henry J. Kaiser Family Foundation, Menlo Park, California."--Verso T.p. Committee chairman: Leslie Z. Benet.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins -- Copyright -- Preface -- Contents -- Summary -- CROSS-CUTTING RECOMMENDATIONS -- USES OF ANTIPROGESTINS: THE REPRODUCTIVE CYCLE -- Contraception -- Post-Coital Contraception -- Menses Induction -- Pregnancy Termination During the First Trimester -- Pregnancy Termination During the Second Trimester -- Cervical Ripening -- Labor Induction in Late Pregnancy -- OTHER POTENTIAL THERAPEUTIC USES OF ANTIPROGESTINS -- Endometriosis -- Uterine Leiomyomas (Fibroids) -- Breast Cancer -- Meningioma -- ANTIGLUCOCORTICOID EFFECTS OF ANTIPROGESTINS -- 1 Introduction -- BACKGROUND AND HISTORICAL PERSPECTIVES -- Finding an Antiprogestin -- THE IOM REPORT -- CROSS-CUTTING

RECOMMENDATIONS -- REFERENCES -- 2 Uses of Antiprogestins: The Reproductive Cycle (Part I) -- CONTRACEPTION -- POST-COITAL CONTRACEPTION -- MENSES INDUCTION -- REFERENCES -- 3 Uses of Antiprogestins: The Reproductive Cycle (Part II) -- PREGNANCY TERMINATION DURING THE FIRST TRIMESTER -- Health Services Research -- PREGNANCY TERMINATION DURING THE SECOND TRIMESTER -- CERVICAL RIPENING -- LABOR INDUCTION IN LATE PREGNANCY -- Fetal Demise -- SUMMARY -- REFERENCES -- 4 Other Therapeutic Uses of Antiprogestins -- ENDOMETRIOSIS -- Utility of Mifepristone (RU 486) for Treatment of Endometriosis -- Summary -- UTERINE LEIOMYOMAS (FIBROIDS) -- Utility of Mifepristone for Treatment of Uterine Leiomyomas -- BREAST CANCER -- Mechanism of Action -- Clinical Issues -- Adjuvant Therapy and Chemoprevention -- Resistance -- Dose Issues -- Conclusions -- MENINGIOMAS -- Conclusions -- REFERENCES -- 5 Antiglucocorticoid Effects of Antiprogestins -- GLUCOCORTICOID FUNCTION -- THERAPEUTIC USE OF MIFEPRISTONE (RU 486) AS ANANTI-GLUCOCORTICOID -- ADVERSE ANTI-GLUCOCORTICOID EFFECTS OF ANTIPROGESTINS -- REFERENCES. 6 Animals as Models for Studying Antiprogestins -- REFERENCES -- APPENDIXES -- A Agenda for the IOM Workshop "Antiprogestins: Assessing the Science," April 13-14, 1993 -- B Background Papers and Presentations (In Order of Presentation at IOM Workshop) -- B1 1993: RU 486-A DECADE ON TODAY AND TOMORROW -- ANTIHORMONES: THE 20 YEARS BEFORE RU 486 -- CHEMISTRY: NOVEL MOLECULES -- CELLULAR AND MOLECULAR MECHANISMS OF ACTION OF ANTIPROGESTINS: THE RECEPTOR AT THE CENTER -- Ligand Binding -- Receptor Transconformation -- Heat Shock Protein Binding -- Receptor Dimerization -- Binding to DNA -- Studies of Chromatin -- Gene Transcription -- PHYSIOPHARMACOLOGICAL REPRODUCTIVE EFFECTS -- REPRODUCTIVE MEDICINE (TABLE B1.4) -- Voluntary Early Pregnancy Interruption -- Pregnancy Interruption After Nine Weeks of Amenorrhea -- Initiation of Labor -- Contragestive and Contraceptive Methods Using RU 486 -- Emergency Post-Coital Contraception (Contraceptive or Contragestive According to When it is Applied) -- Late Luteal Phase Administration (Occasional Use) (Contragestive) -- Monthly Premenstrual, Late Luteal Phase Administration (Repeated Use) (Contragestive) -- Early Luteal Phase Administration (Once a Month) (Anti-Implantation) -- Endometrial Contraception" (Daily Delivery of Very Low Dose) (Contraceptive and Contragestive) -- Ovulation Suppression (Daily Delivery of a Low Dose) (Contraceptive) -- Male Contraception -- MEDICAL APPLICATIONS (TABLE B1.4) -- Uterine Diseases -- Endometriosis -- Fibroids -- Breast Cancer -- Meningioma -- ANTI-GLUCOCORTICOSTEROID EFFECTS -- CONCLUSIONS -- Use for Voluntary Pregnancy Interruption -- Contraception -- Cancer -- Novel Antiprogestins: Biology and Chemistry -- ACKNOWLEDGMENTS -- REFERENCES -- B2 OVERVIEW AND BACKGROUND: MECHANISM OF ACTION OF ANTIPROGESTINS -- INTRODUCTION -- STRUCTURE AND FUNCTION OF THE PROGESTERONE RECEPTOR. The Hormone Binding Domain -- The DNA Binding Domain -- Transactivation Function -- Association with Other Proteins -- Phosphorylation of the Progesterone Receptor -- Progesterone-Receptor Function -- MECHANISMS OF ACTION OF PROGESTERONE ANTAGONISTS -- Binding of Antagonists to Progesterone Receptors -- Formation of Dimers and DNA Binding Complexes -- Effects of Antagonists on Transcriptional Activation -- Other Effects of Antagonists on Receptors -- SUMMARY AND FUTURE AREAS OF STUDY -- REFERENCES -- B3 THE USE OF ANTIPROGESTINS IN THE REPRODUCTIVE CYCLE -- USE OF ANTIPROGESTINS IN THE

REPRODUCTIVE CYCLE -- Basic Concepts and Assumptions --
Assessment Issues in Evaluating Antiprogestins -- Potential Uses of
Antiprogestins -- Follicular Phase Administration of RU 486 -- Other
Strategies for Administration of RU 486 During the Menstrual Cycle --
TOXICITY -- QUESTIONS FOR FUTURE RESEARCH -- SUMMARY --
REFERENCES -- B4 POTENTIAL CONTRACEPTIVE EFFECTS OF
ANTIGESTOGENS -- ABSTRACT -- INTRODUCTION -- PHYSIOLOGICAL
STUDIES IN THE MENSTRUAL CYCLE -- POSSIBLE CONTRACEPTIVE USES
OF MIFEPRISTONE -- Inhibition of Ovulation -- Post-Coital
Contraception -- Endometrial Contraception -- Late Post-Coital
Contraception -- FUTURE DEVELOPMENTS -- Basic Research -- Mode
of Action -- Clinical Studies -- REFERENCES -- B5 USE OF
ANTIPROGESTINS BEFORE 63 DAYS OF AMENORRHEA -- INTRODUCTION
-- EFFECT OF MIFEPRISTONE DURING EARLY PREGNANCY --
TERMINATION OF EARLY PREGNANCY -- Mifepristone Alone --
Mifepristone in Combination with Prostaglandin -- Practical Guidelines
for Clinical Use of Mifepristone in Combination with Prostaglandin --
FURTHER DEVELOPMENTS IN MEDICAL TERMINATION OF EARLY
PREGNANCY -- CONCLUSIONS -- REFERENCES -- B6 USES OF
ANTIPROGESTINS AFTER 63 DAYS OF AMENORRHEA -- RU 486 FOR
SECOND-TERM PREGNANCY TERMINATION -- RU 486 FOR
INTRAUTERINE FETAL DEATH (IUFD).
CERVICAL RIPENING WITH RU 486 PRIOR TO SURGICAL ABORTION -- RU
486 FOR LABOR INDUCTION -- REFERENCES -- B7 COMMENTS ON
SESSION II -- USE OF MIFEPRISTONE AND PROSTAGLANDIN FOR FIRST-
TRIMESTER ABORTION -- Need for Medical Supervision -- Acceptability
of Medical Versus Surgical Abortion -- Number of Visits Required --
Appropriate Dose of Mifepristone -- Side Effects -- SECOND-
TRIMESTER ABORTIONS -- CONTRACEPTION -- POST-COITAL
CONTRACEPTION -- CERVICAL RIPENING -- SUMMARY -- B8 USE OF
ANTIPROGESTINS IN THE MANAGEMENT OF ENDOMETRIOSIS AND
LEIOMYOMA -- ABSTRACT -- INTRODUCTION -- ENDOMETRIOSIS --
Antiprogestin in the Treatment of Endometriosis -- Pilot Study --
Long-Term, Low-Dose Studies -- LEIOMYOMA (FIBROID TUMOR) --
Antiprogestin in the Management of Leiomyoma- Dose-Response
Studies -- 50-mg Dose -- 25- and 5-mg Doses -- Outcome --
ACKNOWLEDGMENTS -- REFERENCES -- B9 ANTIPROGESTINS AND THE
TREATMENT OF BREAST CANCER -- INTRODUCTION -- PROGESTERONE
AND THE NORMAL BREAST -- PROGESTERONE AND BREAST CANCER --
Progestin Agonists and Tumor Induction -- Progestin Agonists and
Growth of Established Tumors -- PROGESTERONE ANTAGONISTS AND
THE TREATMENT OF BREAST CANCER -- Human Breast Cancer Cell
Lines -- Animal Models of Mammary Cancer -- Human Clinical Trials
-- PROGESTIN RESISTANCE -- SUMMARY AND FUTURE PROSPECTS --
REFERENCES -- B10 USES OF RU 486 AS AN ANTIGLUCOCORTICOID --
HOW DO GLUCOCORTICIDS ACT? -- PHYSIOLOGIC ROLE OF
GLUCOCORTICIDS -- RU 486 AS AN ANTIGLUCOCORTICOID --
RESEARCH DIRECTIONS FOR ANTIGLUCOCORTICIDS -- REFERENCES --
B11 PRIMATE MODELS FOR THE STUDY OF ANTIPROGESTINS IN
REPRODUCTIVE MEDICINE -- PART I: ACTIVITY EXPRESSIONS OF
ANTIPROGESTINS -- Progesterone Antagonists -- Antiglucocorticoid
Activity -- Noncompetitive Antiestrogenic (Antiproliferative) Activity --
Sources of Antiprogestins.
PART II: NONCOMPETITIVE ANTIESTROGENIC ACTIVITY OF
PROGESTERONE ANTAGONISTS -- Initial Evidence of Noncompetitive
Antiestrogenic Activity of Mifepristone -- Dose-Dependent Blockade of
the Proliferative Action of Estradiol Endometrium by Mifepristone --
Mifepristone-Induced Elevations of Estrogen Receptor in Primate

Endometrium -- REFERENCES -- B12 ANTIPROGESTOGENS:
PERSPECTIVES FROM A GLOBAL RESEARCH PROGRAM -- ABSTRACT --
INTRODUCTION -- COMPOUNDS -- Progesterone Synthesis Inhibitors
-- Progesterone-Receptor Blockers -- ANIMAL MODELS -- Receptor
Binding -- Plasma Protein Binding -- Pregnant Guinea Pig Model --
MECHANISMS OF ACTION -- Prostaglandin Metabolism -- Myometrial
Gap Junctions -- Estrogen and Progesterone Receptors -- POSSIBLE
USES -- PROSPECTS -- ACKNOWLEDGMENT -- REFERENCES -- C
Observers at the Workshop on Antiprogestins: Assessing the Science
April 13-14, 1993 -- Index.
